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hajaae@yahoo.coAbstract This paper describes two simple spectrophotometric methods for the determination of
the antibiotic gemiﬂoxacin mesylate (GFX) in pharmaceutical formulations. The ﬁrst (A) is an
indirect method in which oxidation of the drug with a known excess of cerium (IV) sulphate is
followed by determination of the residual oxidant by adding excess methyl orange and measuring
residual dye at 507 nm. The second (B) is a derivatisation method involving reaction of GFX with
1,2-naphthoquinone-4-sulphonate (NQS) in alkaline medium (pH 11) to form an orange-coloured
product exhibiting maximum absorption (lmax) at 411 nm. The methods were linear in the
concentration ranges 2–9 and 5–30 mg/mL for methods A and B, respectively, with intra-day
precision (as RSD)o1.5% for both. When applied to the determination of GFX in pharmaceutical
tablets, the results were in good agreement with those obtained by capillary electrophoresis. The
two methods are useful for routine analysis of GFX in quality control laboratories.
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Over the last twenty years, ﬂuoroquinolones have emerged as
one of the most important classes of antibiotics1. Gemiﬂoxacin
mesylate (GFX) [(R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyi-
mino)-1-pyrrolidinyl]-1-cyclopropyl-6-ﬂuoro-1,4-dihydro-4-
oxo-1,8-naphthyridine-3-carboxylic acid mesylate] is a fourth
generation ﬂuoroquinolone used for the treatment of pneu-
monia and bronchitis2. It is also currently under review by the
U.S. Food and Drug Administration for the treatment of
upper respiratory tract infections3.
A number of analytical methods have been reported for the
determination of GFX in pharmaceutical dosage forms including
capillary electrophoresis4, reversed phase high performance liquid
chromatography (RP-HPLC) with UV and ﬂuorescence detection,
liquid chromatography–tandem mass spectrometry (LC–MS/MS),
spectroﬂuorimetry and spectrophotometry5–10. The electrophoretic
and chromatographic methods require sophisticated and/or
expensive instruments and, although spectroﬂuorimetry is a simple
technique, the only reported spectroﬂuorimetric method8 involves
an extraction step and heating to 80 1C.
Spectrophotometry is probably the most convenient analytical
technique for routine analysis because of its inherent simplicity,
low cost and wide availability in quality control laboratories. Two
spectrophotometric methods have been previously reported for the
determination of GFX9,10. One was based on the charge transfer
complexation reaction of GFX with iodine and 2,3-dichlo-
ro-5,6-dicyano-p-benzoquinone-7,7,8,8-tetracyanoquinodimethane
(TCNQ) and tetracyanoethylene (TCNE)9, and the other on ion-
pair complex formation with safranin O and methylene blue in
basic medium or napthol blue 12BR and azocaramine G in acidic
medium10. The two methods are associated with major drawbacks
such as the need for multiple extraction steps in the latter and for
GFX free base in the former. In this paper, we report two new
spectrophotometric methods for the determination of GFX in
pharmaceutical tablets that overcome these drawbacks.
2. Materials and methods
2.1. Instrumentation
Absorbance was measured in 1 cm quartz cuvettes using a
double beam UV-1800 ultraviolet–visible spectrophotometer
(Shimadzu, Japan) with temperature maintained at 25 1C. pH
was determined using a model pH211 pH meter (Hanna, Italy).
2.2. Materials
All chemicals used were of analytical reagent grade. Chemicals
(suppliers) were as follows: Cerium (IV) sulphate (Loba-
Chemie Indoaustranal Co., India); methyl orange (MO, Fluka
Chemika Sigma-Aldrich); sulphuric acid (S. d. Fine Chem,
Mumbai, India); sodium 1,2-naphthoquinone-4-sulphonate
(NQS) (Aldrich Chemical Co., St. Louis, USA). Doubly
distilled water was used to prepare all solutions.
2.3. Reagents
2.3.1. Cerium (IV) sulphate (250 mg/mL)
A 0.01 g/mL cerium (IV) sulphate solution was prepared by
dissolving 0.5 g in 50 mL of 1.0 mol/L sulphuric acid. Thisstock solution was diluted with 1 mol/L sulphuric acid to
produce a 250 mg/mL solution.
2.3.2. Methyl orange (50 mg/mL)
A 500 mg/mL solution was prepared by dissolving 50 mg in
100 mL water. After ﬁltration, the solution was diluted 10-fold
to obtain 50 mg/mL working solution.
2.3.3. Sulphuric acid (5 mol/L)
This was prepared by adding 274 mL concentrated sulphuric
acid to 726 mL water with cooling.
2.3.4. NQS (0.3%, w/v)
This was prepared by adding 150 mg NQS in 50 mL water.
The solution was freshly prepared and protected from light
during use.
2.3.5. Buffer solution pH 11.0
This was prepared by adding 55 mL 0.2 mol/L NaOH and
35 mL 0.2 mol/L NaH2PO4 to 100 mL water and adjusting to
pH 11.0. Other buffer solutions were also prepared according
to literature methods.
2.4. Preparation of GFX stock and sample solutions
2.4.1. GFX stock solution
A stock solution (1 mg/mL) of GFX was prepared by dissol-
ving 10 mg of pure drug in 10 mL water.
2.4.2. Sample solution
A sample of ﬁnely powdered tablet nominally equivalent to
100 mg GFX was dissolved in about 40 mL distilled water in a
100 mL volumetric ﬂask. After shaking for 15 min, the con-
tents were made up to volume with water, ﬁltered (rejecting
the ﬁrst portion of the ﬁltrate) and the ﬁltrate diluted to obtain
a suitable concentration for the analysis.
2.5. Assay procedures
2.5.1. Method A
Aliquots of the GFX stock solution were added to 10 mL
volumetric ﬂasks to give ﬁnal concentrations of 2–9 mg/mL.
Each ﬂask was added 1 mL of 5 mol/L sulphuric acid and
1 mL of 250 mg/mL cerium (IV) sulphate solution. After
mixing, ﬂasks were allowed to stand at room temperature
for 10 min with occasional swirling. Finally 1 mL of 50 mg/mL
methyl orange solution was added and the solution diluted to
the mark with water and mixed. After 5 min, the absorbance
of each solution was measured at 507 nm against a reagent
blank prepared in the same manner using 1 mL water instead
of 1 mL methyl orange solution.
2.5.2. Method B
Aliquots of GFX solution were added to 10 mL volumetric
ﬂasks to give ﬁnal concentrations of 5–30 mg/mL. Buffer
solution (pH 11.0, 1 mL) was added followed by 1 mL NQS
solution (0.3%, w/v). The reaction was allowed to proceed at
room temperature for 15 min after which the reaction mixture
was made up to the mark with water and the absorbance
measured at 411 nm against a water blank similarly prepared.
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Calibration curves were prepared and used to calculate the
limit of detection (LOD) and limit of quantitation (LOQ)
using the formula LOD or LOQ¼kSD/b, where k is 3.3 for
LOD and 10 for LOQ, SD is the standard deviation of the
intercept and b is the slope. Concentrations of GFX in the
tablet samples were determined from the calibration curves or
from the respective regression equations. The accuracy (as
relative error, RE) and intra-day precision (also called repeat-
ability; as relative standard deviation, RSD) of the methods
were evaluated by performing ﬁve replicate analyses of pure
drug solutions at three different concentrations within the
working ranges. The inter-day precision (also called reprodu-
cibility) was assessed by performing ﬁve replicate analyses of
pure drug solutions at three concentrations over a period of
ﬁve days using freshly prepared solutions on each day. The
accuracy and precision of the method were further assessed by
measuring recovery using powdered tablets spiked with GFX
at three different concentrations. Each assay was performed in
triplicate.Figure 1 Absorption spectra of GFX (30 mg/mL) against water
(1), NQS (0.3%, w/v) against water (2), and the reaction product
of GFX (30 mg/mL) with NQS against reagent blank (3).
Figure 2 Effect of standing time on the reaction of GFX with
CeSO4. GFX (3 mg/mL): 1 mL; H2SO4 (5 mol/L): 1 mL; CeSO4
(250 mg/mL): 1 mL; MO (50 mg/mL): 1 mL; temperature: 25 1C.3. Results and discussion
3.1. Method A
The ability of cerium (IV) sulphate to oxidise GFX and
interact with methyl orange is the basis of the indirect
spectrophotometric method (A) developed here. In this
method, excess cerium (IV) sulphate reacts with GFX in acid,
the unreacted oxidising agent reacts with excess methyl orange
and the residual methyl orange is determined by measurement
of its absorbance at 507 nm. The absorbance was found to
increase linearly with increasing concentration of GFX.
3.2. Method B
GFX exhibits maximum absorbance (lmax) at 262 nm.
Being in the ultraviolet, absorbance at this wavelength is
susceptible to interference from co-extracted excipients in the
tablet formulation. Accordingly, derivatization of GFX to
produce a chromophore absorbing more in the visible
region was appropriate. GFX contains a primary aliphatic
amino group, which is suitable for derivatization by NQS, an
analytical chromogenic reagent for the determination of
primary and secondary amines11–13. GFX was found to
react instantaneously with NQS under the experimental con-
ditions to form an orange coloured product exhibiting lmax at
411 nm (Fig. 1). Under the optimum reaction conditions, the
absorbance was found to obey the Beer–Lambert law.
3.3. Optimisation of reaction variables
3.3.1. Method A
Preliminary experiments showed that the maximum concentra-
tion of methyl orange that could be determined spectrophoto-
metrically was 5 mg/mL. A cerium (IV) sulphate concentration
of 25 mg/mL was sufﬁcient to extinguish the red colour of this
methyl orange solution under acidic conditions. Hence, drug
was reacted with 1 mL of 250 mg/mL oxidant solution beforedetermining the residual cerium (IV) sulphate. For quantitative
reaction between the drug and cerium (IV) sulphate, a contact
time of 10 min was found to be sufﬁcient (Fig. 2). A reaction
time of 5 min was sufﬁcient for the reaction between cerium
(IV) sulphate and methyl orange after which the absorbance
was stable for hours.3.3.2. Method B
3.3.2.1. Effect of NQS concentration. The reaction was
found to be dependent on NQS concentration with the
absorbance of the reaction solution increasing as the NQS
concentration increased. Maximum absorbance was attained
at an NQS concentration of 0.3% (w/v) above which it
decreased (Fig. 3).
Figure 3 Effect of NQS concentrations on the reaction of GFX
with NQS. GFX (30 mg/mL): 1 mL; NQS: 1 mL; buffer solution
(pH 11.0): 1 mL; temperature: 25 1C; reaction time: 15 min.
Figure 4 Effect of pH on the reaction of GFX with NQS. GFX
(30 mg/mL): 1 mL; buffer solution of different pH values: 1 mL;
NQS (0.3%, w/v): 1 mL; temperature: 25 1C; reaction time: 15 min.
Figure 5 Effect of standing time on the reaction of GFX with
NQS. GFX (30 mg/mL): 1 mL; buffer solution (pH 11.0): 1 mL;
NQS (0.3%, w/v): 1 mL; temperature: 25 1C.
Figure 6 Job’s method for NQS with GFX.
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requires an alkaline medium. It was found that at pHo6.0 no
GFX-NQS product was formed whereas at pH46.0 the
absorbance due to the product increased rapidly with increas-
ing pH. Maximum absorbance was attained at pH 11.0, and
then decreased probably due to competition by hydroxide ion
for NQS. On this basis, a pH of 11.0 was selected for the
reaction (Fig. 4).3.3.2.3. Effect of reaction time. By following the reaction for
various lengths of time, it was found that the reaction went to
completion over 15 min and a longer reaction time was not
necessary (Fig. 5).3.3.2.4. Stoichiometry of the reaction (Job’s method). Stoi-
chiometry of the reaction was established by Job’s method of
continuous variation14. Equimolar aqueous solutions of GFXand NQS (5 103 mol/L) were prepared in 10 mL volumetric
ﬂasks containing complementary proportions of the two
compounds (0:10, 1:9, y, 9:1, 10:0, inclusive) and 1 mL of
pH 11.0 buffer solution. The Job plot of absorption versus
mole ratio was symmetrical and indicated that a 1:1 complex
(Fig. 6) was formed in the reaction (Scheme 1).3.4. Assay validation
3.4.1. Linearity and sensitivity
Calibration curves for Methods A and B in the ranges 2–9 mg/mL
and 5–30 mg/mL were linear with regression equations (correlation
coefﬁcients) of Y¼0.01044þ 0.05199 (77.17881 104) X
(r¼0.9994) and Y¼0.00357þ 0.01951 (73.15793 104) X
(r¼0.9995), respectively. The molar absorptivities (e) at 507 nm
and 411 nm for Methods A and B were 2.14 103 and
7.61 102L/mol/cm, respectively. Values of LOD and LOQ were
0.27 and 0.82 mg/mL, respectively, for Method A and 1.04 and
3.15 mg/mL, respectively, for Method B. These parameters for the
two methods are summarised in Table 1.
Scheme 1 Proposed reaction pathways between GFX and NQS.
Table 1 Parameters for the performance of the proposed method.
Parameter Method A Method B
Measurement wavelength, nm 507 411
Linear range, mg/mL 2–9 5–30
Molar absorptivity, L/mol/cm 2.117 104 7.523 103
Sandell sensitivity, mg/cm2 0.018 0.052
Limit of detection, mg/mL 0.27 1.04
Limit of quantiﬁcation, mg/mL 0.82 3.15
Regression equation, Ya
Intercept (a) 0.01044 0.00357
Standard deviation of intercept 0.00428 0.00615
Slope (b) 0.05199 0.01951
Standard deviation of slope ( 104) 7.17881 3.15793
Correlation coefﬁcient (r) 0.99943 0.99948
Standard deviation 0.00465 0.00661
aY¼aþbX, where Y is the absorbance, a intercept, b slope and X concentration
in mg/mL.
Table 2 Evaluation of accuracy and precision.
Method Taken Found Range Relative error (%) SD RSD (%)
Method A 4.5 4.51 0.010 0.24 0.004 1.44
5.5 5.49 0.010 0.15 0.004 1.41
6.5 6.49 0.007 0.02 0.003 0.92
Method B 17 17.04 0.012 0.02 0.005 1.48
22 22.09 0.009 0.04 0.004 0.87
27 26.99 0.014 0.03 0.005 1.04
GFX taken/found, range and SD are in mg/mL.
SD, standard deviation; RSD, relative standard deviation.
Mean value of ﬁve determinations.
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Accuracy (RE) was within 0.24% and 0.04% for Methods A
and B, respectively, with corresponding intra-day precision
(RSD)o1.5% for the two methods. The results are compiled
in Table 2. The inter-day precision (RSD) was o3.5%
reﬂecting the validity of the method for routine analysis in
quality control laboratories.3.4.3. Recovery
The percent recoveries of GFX were in the ranges of 99.4–
100.4 and 99.9–100.7 for Methods A and B, respectively
(Table 3). This shows the absence of interference from tablet
excipients.3.4.4. Assay of tablets
The content of tablets was found to be 99.9470.82% and
100.0570.83% of the label claim by Methods A and B,
respectively (Table 4). Statistical analysis (t- and F-tests)
showed there was no signiﬁcant difference between these
values at the 95% conﬁdence level indicating the two methods
have similar accuracy and precision.4. Conclusions
The present study describes the successful development of
two simple spectrophotometric methods for the determination
of GFX in tablets that are superior to previously reported
Table 3 Results of recovery study by standard-addition method.
Method Formulation
studied
Amount of drug in
formulation (mg)
Amount of pure
drug added (mg)
Total found
(mg)
% recovery of
pure druga7SD
RSD% Bias%
Method A Factive tablets
(320 mg)
3 2 4.99 99.8470.03 0.03 0.20
3 3 5.96 99.3570.02 0.02 0.67
3 4 7.03 100.4370.04 0.04 0.43
Method B Factive tablets
(320 mg)
10 5 14.98 99.8970.11 0.11 0.13
10 10 20.13 100.6670.07 0.07 0.65
10 15 25.14 100.5670.10 0.10 0.56
aMean value of three determinations.
Table 4 Application of the proposed and references methods for the analysis of dosage form containing GFX.
Method Brand namea and
dosage form
Label claim
(mg/tablet)
Amount found (% found7RSD)b
Method A Factive tablets 320 319.81 99.9470.82 (2.244, 0.288)
Method B – – 320.16 100.0570.83 (1.951, 0.281)
Reference method4 – – 322.75 100.8670.44
Values in parenthesis are the calculated values of t and F; the tabulated values at 95% conﬁdence limit are 2.776 and 6.26, respectively.
aManufactured by Tabuk Pharmaceutical Mfg. Co., Tabuk, Saudi Arabia.
bValues are mean of ﬁve determinations.
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inexpensive, stable and readily available in any analytical
laboratory. The methods do not require complex procedures
and are highly suitable for routine use in quality control
laboratories.References
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